-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors
-
-
-
-
-
-
-
BioLineRx (BLRX) Reports First Patient Dosing in Part 2 of Phase 1/2a Clinical Study for AGI-134
-
-
-
-
-
-
-
BioLineRx (BLRX) Receives FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134
-
-
-
-
-
-
-
BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical Studies
-
-
-
-
-
-
-
BioLineRx (BLRX) Acquires Agalimmune
-
-
-
-
-
-
-
Pre-Open Stock Movers 3/4: (OXBT) (VIPS) (INSY) Higher; (RSH) (MDR) (MDRL) Lower (more...)
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

